Dyax Corp.
KALBITOR(R) ecallantide Now Commercially Available
Published in Managed Care Business Week, February 16th, 2010
HAE is a rare, genetic disorder characterized by severe, debilitating and often painful swelling, which can occur in the abdomen, face, hands, feet and airway. KALBITOR, a potent, selective and reversible plasma kallikrein inhibitor discovered and developed by Dyax, is the first subcutaneous HAE treatment approved in the U.S.
Orders for KALBITOR will be coordinated through KALBITOR AccessSM. The KALBITOR Access team of dedicated...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
More Articles from Managed Care Business Week
- Advanced Cancer Therapeutics ACT
Advanced Cancer Therapeutics Funds Brown Cancer Center Research Scientist to Accelerate Identification of Clinical Candidates - Agilent Technologies Inc.
Linden Acquires Hycor Biomedical Business from Agilent Technologies - Alere
Alere's Dr. Michael Taitel Presents Compelling Evidence at IBI/NBCH Health & Productivity Forum that Wellness Programs Positively Impact Health & Productivity - Alliance Health Networks, Inc.
Alliance Health Networks Taps Josh DeFord as its Vice President of Product Management - Alorad, Inc.
Strategic Online Marketing Company Alorad, Inc. Creates New Divisions to Keep up with Growth - Alpha II
Alpha II CodeSets Now Offered Directly to Medical Facilities - More from this issue of Managed Care Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
